Analyst Activity – B. Riley Initiates Coverage On Apellis Pharmaceuticals (NASDAQ:APLS) With a Buy

Analyst Ratings For Apellis Pharmaceuticals (NASDAQ:APLS)

Story continues below

Today, B. Riley initiated coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy with a price target of $27.00.

Some recent analyst ratings include

  • 2/8/2018-B. Riley initiated coverage with a Buy rating.
  • 12/4/2017-Evercore ISI initiated coverage with a Outperform rating.
  • 12/4/2017-Citigroup initiated coverage with a Buy rating.
  • 12/4/2017-JPMorgan Chase & Co. initiated coverage with a Overweight rating.


  • On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.

Recent Trading Activity for Apellis Pharmaceuticals (NASDAQ:APLS)
Shares of Apellis Pharmaceuticals closed the previous trading session at 16.58 up +1.49 9.87% with shares trading hands.

An ad to help with our costs